Skip to content


Opsumit (macitentan) is a small molecule pharmaceutical. Macitentan was first approved as Opsumit on 2013-10-18. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against endothelin-1 receptor. In addition, it is known to target endothelin receptor type B. Opsumit's patents are valid until 2029-04-18 (FDA).
Trade Name Opsumit
Common Name Macitentan
Indication pulmonary hypertension
Drug Class Endothelin receptor antagonists
Get full access now